Wedbush analyst Andreas Argyrides raised the firm’s price target on Ascendis Pharma to $192 from $187 and keeps an Outperform rating on the shares after the company reported Q2 financials and provided key business updates. U.S. regulatory timeline for TC-PTH is becoming clearer, with all eyes on NDA acceptance, Wedbush says.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ASND:
- Ascendis Stock (NASDAQ:ASND): Investors and Analysts are Bullish Post Q2 Results
- Ascendis Pharma price target lowered to $134 from $139 at Wells Fargo
- Ascendis Pharma up 6% at $106 after Q2 results, SKYTROFA revenue outlook raise
- Ascendis: eGFR improved in TransCon PTH-treated adults with hypoparathyroidism
- Ascendis Pharma says decision on MAA for TransCon PTH expected during Q423
